<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03614481</url>
  </required_header>
  <id_info>
    <org_study_id>COLLECTION DMLA</org_study_id>
    <secondary_id>2013-A00110-45</secondary_id>
    <nct_id>NCT03614481</nct_id>
  </id_info>
  <brief_title>Clinical and Genetic Analyzes of Age-related Macular Degeneration</brief_title>
  <acronym>COLDMLA</acronym>
  <official_title>Clinical and Genetic Analyzes of Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Intercommunal Creteil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Intercommunal Creteil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this collection is to search for susceptibility genes for age-related macular
      degeneration (AMD) alone or in combination with environmental factors and to look for genes
      that modulate the AMD phenotype (particularly the response to treatment).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2005</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genotypic factors</measure>
    <time_frame>6 months</time_frame>
    <description>Identification of genotypic factors associated with good or poor response to treatment in precisely phenotyped AMD patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predictive markers</measure>
    <time_frame>6 months</time_frame>
    <description>Look for predictive markers of cure response among polymorphisms that are susceptibility factors for AMD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular Endothelial Growth Factor</measure>
    <time_frame>6 months</time_frame>
    <description>Look for predictors of treatment response among polymorphisms of other genes: Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor Receptor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Environmental factors</measure>
    <time_frame>6 months</time_frame>
    <description>Look for predictive markers of treatment response among environmental factors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictive treatment response score</measure>
    <time_frame>6 months</time_frame>
    <description>Create a predictive treatment response score that combines factors independently associated with the response to treatment in multivariate analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating biological factors</measure>
    <time_frame>6 months</time_frame>
    <description>Identification of circulating biological factors such as circulating fatty acids at risk of AMD or modulating the response to treatment.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">6000</enrollment>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>AMD patient</arm_group_label>
    <description>During the AMD consultation, patients have their imaging exams including OCT, retinophotography, and fluorescein angiography.
After the interview with the doctor on pathology diagnosis and follow-up, they will meet the clinical research associate nurse to complete the questionnaire and perform anthropometric measurements (weight, height, abdominal perimeter measurement and blood pressure measurement). Patients recruited at Créteil will benefit from a venous blood sample (20 mL) in 2 EDTA tubes for DNA extraction after light reading and signature of consent. For patients recruited from other ophthalmic centers, the Clinical Research Associate will perform salivary sampling for DNA extraction after light reading and signature of consent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control without AMD</arm_group_label>
    <description>898/5000 Given the observation of a mutation in an unaffected control individual, it is not excluded that this individual may be suffering from AMD at a later age. The observation of the mutation could thus be considered as a pre-clinical test. None of the teams were able to obtain a control population of the same age and sex ratio, which could have benefited from fluorescein angiography or at least a fundus examination, to ensure the absence of warning signs of AMD. This requires cooperation from healthy elderly volunteers not only for blood sampling but also for pupillary dilatation.
The controls may be the accompanying persons or spouses of AMD patients. It may also be people seen in general consultation without maculopathy or retinopathy with an age greater than 55 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Sampling</intervention_name>
    <description>Sampling</description>
    <arm_group_label>AMD patient</arm_group_label>
    <arm_group_label>control without AMD</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      salivary swabs, venous sampling
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Diagnosis of exudative or atrophic AMD
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt; 55 years

          -  Diagnosis of exudative or atrophic AMD in at least one eye

          -  Patient informed of the objectives of the study and having freely signed the informed
             consent letter

          -  Patient affiliated to a social security scheme

        Exclusion Criteria:

          -  Other retinal or choroidal lesion in the studied eye

          -  History of severe systemic disease that could potentially hinder patient adherence to
             the study protocol: mental disorder, cancer, recent stroke or heart failure less than
             3 months old.

          -  Known allergy to fluorescein, indocyanine green, iodine or ranibizumab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Eric Soueid</last_name>
    <email>eric.souied@chicreteil.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François Korobelnik, MD, PhD</last_name>
      <email>jean-francois.korobelnik@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHI Créteil</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Soueid</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital général de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Creuzot-Garcher, MD PhD</last_name>
      <email>catherine.creuzot-garcher@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital des Quinze-Vingts</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José-Alain Sahel, MD PhD</last_name>
      <email>j.sahel@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre ophtalmologique d'imagerie et de laser</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cohen</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 30, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>July 30, 2018</last_update_submitted>
  <last_update_submitted_qc>July 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

